Experts Call For More Clinical Trials Of Percutaneous Circulatory Devices
This article was originally published in The Gray Sheet
Executive Summary
A new multi-society clinical expert consensus statement on percutaneous mechanical circulatory support is intended to help physicians select devices for the patients who are most likely to benefit, but the authors identify several questions about the devices that need to be addressed in future clinical studies.
You may also be interested in...
Impella 2.5 PMA Gives Abiomed Big Growth Potential For High-Risk PCIs
The approval, the first for a percutaneous hemodynamic support device, frees Abiomed's hand to market the miniature blood pump to a relatively broad patient population, analysts note.
Early Registry Outcomes Suggest TAVR Roll-Out Has Been Successful So Far
The first report from the U.S. TVT Registry of transcatheter aortic valve replacement shows procedural and in-hospital outcomes comparable to those seen in randomized trials and international registries.
Japan Law Revisions Allow Medical Cannabis But Tighten Other Restrictions
After years of discussions, Japan has revised legislation relating to the use of medicines containing cannabinoids, while also officially criminalizing the non-medical use of marijuana. The move may pave the way for easier use of medicines such as Epidiolex, for which a local Phase III trial started in 2022.